Breaking News

Samsung BioLogics Licensed by Health Canada

To manufacture a monoclonal antibody drug substance at its first plant

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung BioLogics has been licensed by Health Canada for manufacturing a monoclonal antibody drug substance at its first plant in Incheon, Korea.   This is milestone for Samsung BioLogics as it’s another global regulatory agency approval in addition to FDA, EMA, and PMDA. To date, Samsung BioLogics has received 14 global manufacturing approvals for 14 biologics products. The company expects the number of global approvals to reach 30 this year.    Samsung BioLogics also received an approval f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters